Aptevo Therapeutics Inc. (APVO) stock
Close on Nov 12, 2026Market cap $1.19MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.19M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.20
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$26.41M
- EPS, diluted
- -$87.27
- Book value per share
- $5.05
- Diluted shares
- 1M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $0.76
- Open
- $0.77
- Day's range
- $0.65 – $0.77
- Volume
- 235,411
- Average volume (20 days)
- 80,401
- Beta (5 years)
- 0.79
- 52-week range
- $0.65 – $27.72
- RSI (14 days)
- 11.9
- Volatility (1 year)
- 96.0%
- Relative volume
- 2.35×
- WACC
- 8.8%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | APVO | S&P 500 | Difference | APVO per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -64.1% | -2.7% | −61.4 pts | ||
| 3 months | -81.1% | -1.7% | −79.4 pts | ||
| Year to date | -93.0% | +11.9% | −104.9 pts | ||
| 1 year | -97.5% | +12.0% | −109.5 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -98.1% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -96.0% | +11.6% |
| 10 years | -100.0% | +309.6% | −409.6 pts | -82.0% | +15.1% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aptevo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- News
About Aptevo Therapeutics
Pharmaceutical Preparations
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and development of novel immunotherapy candidates for the treatment of various cancers. The company leverages its proprietary ADAPTIR and ADAPTIR-FLEX protein technology platforms to engineer monospecific and multi-specific antibody-based therapeutics designed to harness the immune system against cancer cells. Its pipeline includes clinical candidates such as mipletamig, a CD123xCD3 T cell engager targeting acute myeloid leukemia, and ALG.APV-527, a bispecific molecule targeting 4-1BB and 5T4 developed for solid tumors, alongside several preclinical programs.
Company profile, executives and historyAptevo Therapeutics stock: common questions
What is Aptevo Therapeutics's stock price?
APVO closed at $0.66 on Nov 12, 2026, down 13.14% on the day. Over the past 52 weeks it traded between $0.65 and $27.72.
What is Aptevo Therapeutics's market cap?
Aptevo Therapeutics was worth $1.19M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is APVO's P/E ratio?
Aptevo Therapeutics lost money over fiscal 2025 (diluted EPS -$87.27), so it has no meaningful P/E ratio.
Does Aptevo Therapeutics pay a dividend?
No. Aptevo Therapeutics has not paid a cash dividend over the last twelve months.
When does Aptevo Therapeutics report earnings next?
Aptevo Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has APVO stock performed over the past year?
Including dividends, APVO returned -97.5% over the past year, against +12.0% for the S&P 500.
How many APVO shares are sold short?
0M shares were sold short at the latest FINRA report, 4.61% of the float, or 1.9 days of average trading volume.
Who are Aptevo Therapeutics's competitors?
Companies most similar to Aptevo Therapeutics by business, industry and size include ANIX, BOLT, TNGX, ALXO, XLO.
See a number that looks wrong?